MolMed is developing two novel investigational treatments, prototypes of new therapeutic classes, resulting from two different technological approaches,as well as a third immunogenic innovative therapy:

  • TK, a cell therapy product for the treatment of haematological malignancies, which provides for the treatment of patients undergoing haplo-identical bone marrow transplantation with cells genetically modified ex vivo to express a gene allowing prompt control and abrogation of the possible onset of Graft versus Host Disease (GvHD) reaction.
  • NGR-hTNF, a recombinant biological drug for the treatment of solid tumours, which displays antitumour activity through its specific binding to blood vessels feeding the tumour mass.
  • CAR-CD44v6 , an immuno-gene therapy project potentially effective for many haematological malignancies and several epithelial tumours, currently in preclinical development.

MolMed S.p.A. Via Olgettina, 58 - 20132 Milano, Italy | Phone +39 0221277.1 - Fax +39 02 21277.325 | -
Privacy & Cookie Policy | Suppliers' Privacy Policy | Customers' Privacy Policy
Share capital € 21,819,020.83 fully paid - Office of Milan Company Registry number 1506630 - Tax identification number 11887610159